Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lung Cancer
NEJ009 Study: Gefitinib Alone versus Gefitinib + Chemotherapy for EGFR-Mutant NSCLC
Read More
Lung Cancer
GEOMETRY Mono-1 Study: Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC
Read More
Lung Cancer
IMpower150 Study: Atezolizumab in Combination with Bevacizumab and Chemotherapy in EGFR-Mutated NSCLC
Read More
Lung Cancer
Tarloxotinib in Patients with Advanced NSCLC Harboring an EGFR Exon 20 Insertion or HER2-Activating Mutation
Read More
Lung Cancer
Capmatinib + Nazartinib for EGFR-Mutant NSCLC
Read More
Lung Cancer
NSCLC Year in Review Introduction
Read More
Lung Cancer
Upfront Local Radiation Therapy and First-Line TKI versus TKI Alone in Previously Untreated EGFR-Mutated Oligometastatic NSCLC
Read More
Lung Cancer
Selpercatinib Shows Antitumor Intracranial Activity in RET Fusion–Positive Patients with NSCLC and CNS Metastases
Read More
Lung Cancer
Sym015 Showed Similar Response Rate to MET TKI in Patients with METAmp/Ex14Δ NSCLC
Read More
Lung Cancer
RELAY Results: Patients with Exon 21 L858R or Exon 19 Deletion Mutations of EGFR Benefit from Ramucirumab + Erlotinib
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 30